Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

No statistically significant change in MADRS total score was observed with solriamfetol vs placebo in the overall study population. Topline results were announced from a phase 3 trial evaluating ...

Please provide your email address to receive an email when new articles are posted on . Using baseline scores as reference points, three measures of cognitive function improved more when patients ...